warning_amberWhat You Should Know

Compounded Semaglutide

What compounded means, why it spread during the shortage, what changed when the FDA declared that shortage resolved, and the risks the FDA has documented.

Compounded semaglutide is a non-FDA-approved version of the active molecule in Ozempic, Wegovy, and Rybelsus, prepared by a compounding pharmacy rather than a manufacturer. During the FDA's official shortage period, federal law allowed compounding pharmacies to prepare a version of the drug when a shortage existed. That window closed in late 2024.

This guide walks through what compounding actually is, where things stand legally as of 2026, and the specific risks the FDA has documented — without dismissing why patients turned to compounded versions in the first place. Pricing was the biggest single driver: monthly compounded semaglutide often ran a fraction of brand-name retail, and tens of thousands of patients without coverage relied on it during the shortage. The trade-offs are real on both sides.

The legal and regulatory picture is moving quickly. Treat the dates in this article as a snapshot, not a permanent rule.

What it actually is

A "compounded" drug is one prepared by a pharmacist for an individual patient, traditionally to address a specific need that an FDA-approved product cannot meet — for example, a child-sized dose, a dye-free version, or a topical that doesn't exist commercially. Compounded drugs are not FDA-approved as products. The FDA evaluates manufacturers' finished products for identity, potency, purity, and labeling; compounded drugs are regulated mainly through state boards of pharmacy with some federal oversight from the FDA.

Two categories of compounding pharmacy matter for GLP-1s. 503A pharmacies are traditional state-licensed compounding pharmacies that prepare patient-specific prescriptions. 503B outsourcing facilities are federally registered facilities that can make larger batches under stricter quality standards. Most consumer-facing compounded semaglutide during the shortage came from 503A pharmacies, often through telehealth platforms that paired a prescriber with a partner pharmacy.

Compounded semaglutide is not generic semaglutide. There is no FDA-approved generic for semaglutide. A generic, when one eventually exists, would have to demonstrate bioequivalence to the brand and would be approved by the FDA as a finished product. Compounded versions skip that approval entirely.

Where things stand in 2026

The FDA added semaglutide products to its drug shortage list in August 2022 as demand outpaced Novo Nordisk's manufacturing. That listing was the legal hook that let compounders prepare semaglutide for the broader market. In October 2024, the FDA declared the semaglutide shortage resolved. After a litigation pause and a transition window, 503A pharmacies were generally expected to stop compounding semaglutide in early 2025, and 503B outsourcing facilities followed shortly after.

As of 2026, broad legal commercial compounding of semaglutide for routine weight management has ended. Some 503A pharmacies still argue for clinical-need exceptions — for example, a documented allergy to an inactive ingredient in the FDA-approved product, or a need for a non-standard dose the manufacturer does not make. Whether those exceptions are accepted depends on the specifics, the state, and current FDA enforcement priorities, which continue to evolve.

Several telehealth platforms that built their business on compounded GLP-1s have shifted patients onto the manufacturers' direct self-pay programs (Novo Nordisk's NovoCare Pharmacy for Wegovy, Eli Lilly's LillyDirect for Zepbound). Others have moved into adjacent compounded peptides or shut their compounded GLP-1 services entirely.

The real risks

The FDA has flagged a consistent pattern of harm tied to compounded semaglutide. Dosing errors lead the list. Compounded products are usually shipped as a multi-dose vial with a syringe rather than a pre-filled pen with click-based dose marks. Multiple FDA safety communications have documented patients drawing up 10 times the intended dose — for example, drawing "10 units" on an insulin syringe when the prescription called for "1 mg" — and ending up in the emergency room with severe nausea, dehydration, and prolonged vomiting.

Identity and potency are the second cluster. Some compounded products were prepared with semaglutide sodium or semaglutide acetate, salt forms that have never been studied in humans and that are not the form used in Ozempic or Wegovy. The FDA has explicitly warned that these salt formulations have not been shown to be safe or effective. Patients usually cannot tell from a vial label which form they received.

What to watch for

warning

Dosing errors

Most common adverse event. A 1 mg semaglutide dose looks tiny in an insulin syringe — confusing 'units' with 'mg' leads to massive accidental overdose. If you have a compounded vial, have a pharmacist or nurse walk you through the exact draw.

biotech

Identity and potency

Compounded vials can contain semaglutide base, semaglutide sodium, or semaglutide acetate. Only the base form is in FDA-approved products. Salt forms have unknown safety, and FDA does not test compounded products for potency or sterility.

verified_user

Pharmacy verification

Look up the pharmacy with your state board of pharmacy. Ask whether the active ingredient is sourced from an FDA-registered facility and which salt form they use. A pharmacy that won't answer these questions is a red flag.

Common questions

Common Concerns

Is compounded semaglutide legal in 2026?expand_more

Broad commercial compounding of semaglutide for weight management is no longer legally protected the way it was during the shortage. Patient-specific compounding for documented clinical needs (such as an allergy to an inactive ingredient in the FDA-approved product) may still happen on a case-by-case basis, but routine telehealth-driven compounding for general weight loss has largely ended. Rules continue to evolve — confirm with your state board of pharmacy and the FDA.

Why was compounded semaglutide so much cheaper than Wegovy?expand_more

Compounded versions skipped the manufacturer's research, FDA approval, and brand pricing. Pharmacies sourced bulk active ingredient — often imported — and prepared multi-dose vials, which are far cheaper to make than pre-filled pens. None of that pricing reflected an FDA quality review.

Can I switch from compounded back to brand-name semaglutide?expand_more

Yes. Most patients can transition by getting a prescription for Wegovy or Ozempic from their prescriber. Dose conversion is not always one-to-one — compounded doses were often customized — so your provider may restart titration or hold you at a similar weekly milligram dose. If you're using a manufacturer self-pay program (NovoCare Pharmacy), the same prescription channel handles the switch.

What is microdosing semaglutide, and is it safer than the labeled doses?expand_more

Microdosing means using doses smaller than the FDA-approved titration schedule — for example, 0.1 mg or 0.2 mg per week instead of the standard 0.25 mg start. It is not approved, not studied in randomized trials, and not in any prescribing label. Some patients believe small doses cause fewer side effects; others find them ineffective. There is no clinical evidence either way.

How do I verify a compounding pharmacy is legitimate?expand_more

Check the pharmacy's license with your state board of pharmacy. For 503B outsourcing facilities, look up the facility on the FDA's published 503B registration list. Ask the pharmacy: which API supplier they use, whether the supplier is FDA-registered, which salt form they compound, and how the product is tested for potency and sterility. Reputable pharmacies answer these questions in writing.

Keep exploring

Browse all dosing guides.